載入...
吉非替尼治疗127例晚期复发非小细胞肺癌患者分类及回归树分析
BACKGROUND AND OBJECTIVE: It has been proven that gefitinib produces only 10%-20% tumor regression in heavily pretreated, unselected non-small cell lung cancer (NSCLC) patients as the second- and third-line setting. Asian, female, nonsmokers and adenocarcinoma are favorable factors; however, it is d...
Na minha lista:
| 發表在: | Zhongguo Fei Ai Za Zhi |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
中国肺癌杂志编辑部
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5999611/ https://ncbi.nlm.nih.gov/pubmed/21924034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.04 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|